OraSure Technologies, Inc.  

(Public, NASDAQ:OSUR)   Watch this stock  
Find more results for OSUR
6.29
-0.02 (-0.32%)
Real-time:   12:31PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.16 - 6.34
52 week 4.41 - 10.93
Open 6.32
Vol / Avg. 274,569.00/1.47M
Mkt cap 354.86M
P/E 330.88
Div/yield     -
EPS 0.02
Shares 56.42M
Beta 1.60
Inst. own 84%
Aug 3, 2015
Q2 2015 OraSure Technologies Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 2, 2015
OraSure Technologies Inc at Jefferies Global Healthcare Conference - 10:00AM EDT - Add to calendar
May 18, 2015
OraSure Technologies Inc at UBS Global Healthcare Conference
May 11, 2015
OraSure Technologies Inc Annual Shareholders Meeting
May 6, 2015
Q1 2015 OraSure Technologies Inc Earnings Call - Webcast
May 6, 2015
Q1 2015 OraSure Technologies Inc Earnings Release
Mar 3, 2015
OraSure Technologies Inc at Cowen Health Care Conference
Mar 2, 2015
OraSure Technologies Inc at Raymond James Institutional Investors Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 0.42% -4.33%
Operating margin -1.07% -4.51%
EBITD margin - -3.75%
Return on average assets 0.25% -2.47%
Return on average equity 0.29% -2.89%
Employees 320 -
CDP Score - -

Address

150 WEBSTER ST
BETHLEHEM, PA 18015
United States - Map
+1-503-6416115 (Phone)
+1-610-8821830 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OraSure Technologies is involved in development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. These products include tests for the detection of antibodies to the HIV virus, including the OraQuick In-Home HIV Test, OraQuick ADVANCE Rapid HIV-1/2 Antibody Test and the OraSure HIV-1 Oral Specimen Collection Device, a test for antibodies to the HCV virus, the OraQuick HCV Rapid Antibody Test, and oral fluid testing solutions for drugs of abuse testing, including Intercept Oral Fluid Drug Testing System and Q.E.D. Saliva Alcohol Test. Through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications.

Officers and directors

Douglas G. Watson Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Douglas A. Michels President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald H. Spair Chief Financial Officer, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony II Zezzo II Executive Vice President - Marketing and Sales
Age: 61
Bio & Compensation  - Reuters
Mark L. Kuna Senior Vice President - Finance, Controller, Assistant Secretary
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack E. Jerrett Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Celano Independent Director
Age: 56
Bio & Compensation  - Reuters
Ronny B. Lancaster Independent Director
Age: 63
Bio & Compensation  - Reuters
Charles W. Patrick Independent Director
Age: 60
Bio & Compensation  - Reuters
Roger L. Pringle Independent Director
Age: 74
Bio & Compensation  - Reuters